#Australia #Sydney #Prostate Cancer #Clarity Pharmaceuticals #AMPLIFY trial

Clarity Pharmaceuticals' Milestone in the AMPLIFY Trial

Overview
Clarity Pharmaceuticals (ASX: CU6) has announced a significant achievement in its ongoing Phase III AMPLIFY trial, designed to advance the diagnostic imaging of prostate cancer. With the trial now having consented more participants than initially planned, the demand has been substantial among study sites in the United States and Australia. This recruitment surge reflects a critical step forward in the development of their advanced imaging agent, 64Cu-SAR-bisPSMA.

Details of the AMPLIFY Trial
The AMPLIFY trial is set up as a non-randomised, single-arm, and open-label clinical study focused on evaluating the efficacy of 64Cu-SAR-bisPSMA positron emission tomography (PET) for diagnosing biochemical recurrence (BCR) of prostate cancer. This trial specifically targets men exhibiting rising or detectable levels of prostate-specific antigen (PSA) after initial treatment. The research involves imaging sessions scheduled at two pivotal time points: one on the same day and the other the following day after the administration of the imaging agent.

Initiated in May 2025, this trial aimed to enroll around 220 participants. Clarity Pharmaceuticals has successfully imaged its first participant in the very month of launching the study. The AMPLIFY trial builds upon encouraging results from previous studies, including the Phase I/II COBRA and Phase II Co-PSMA trials, showcasing improved imaging capabilities compared to standard approaches currently used in clinical practice.

Path to FDA Approval
The ultimate goal of this trial is to accrue enough data to support an application to the U.S. Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging tool for patients facing biochemical recurrence of prostate cancer. With the promising preliminary findings from earlier trials, Clarity believes the AMPLIFY trial results will significantly enhance their case for regulatory approval.

Ongoing Research
In addition to the AMPLIFY trial, the company is also running another registrational Phase III trial known as CLARIFY, expected to conclude its recruitment phase later in 2026. This trial aims to further investigate the diagnostic performance of 64Cu-SAR-bisPSMA for detecting prostate cancer in lymph nodes in patients preparing for radical prostatectomy.

Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, emphasized the importance of reaching this recruitment milestone. He highlighted the robust recruitment strategy, which targeted multiple sites across the U.S. and Australia to reflect a diverse patient population and various real-world clinical settings. The initial success indicates a pressing need for improved detection capabilities in the field of prostate cancer, as existing solutions are being challenged by the capabilities of 64Cu-SAR-bisPSMA PET imaging.

Evidence of Demand
To date, Clarity has scanned approximately 600 patients using 64Cu-SAR-bisPSMA and recorded astounding recruitment rates even amid numerous already commercialized standard-of-care products. As many men globally continue to seek more accurate imaging options, Clarity is at the forefront of addressing these needs with innovative solutions that promise not only higher diagnostic efficacy but also enhanced operational flexibility in treatment pathways.

Conclusion
The promising data generated thus far reinforces Clarity Pharmaceuticals' commitment to innovation in prostate cancer diagnostics. With advancements in imaging technologies like 64Cu-SAR-bisPSMA, the company is poised to make substantial contributions to improving patient outcomes in prostate cancer management, marking critical progress on the path to commercialization for their groundbreaking products. As they move forward with both the AMPLIFY and CLARIFY trials, the anticipated results will be crucial in shaping the future of prostate cancer detection.